2 results
Approved WMOCompleted
Primary objectiveTo evaluate if tralokinumab after 14 weeks of treatment (at steady state) changes the metabolism of substrates of CYP 1A2, 2C9, 2C19, 2D6, or 3A4 pathways in subjects with moderate-tosevere atopic dermatitisSecondary objectivesTo…
Approved WMOCompleted
The primary objective of this prospective international multicenter diagnostic study is the comparison of the diagnostic accuracy between copeptin measurement after arginine-stimulation (CAS) and the current best diagnostic test copeptin measurement…